nimodipine has been researched along with Dermatitis Medicamentosa in 2 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nucera, E | 1 |
| Schavino, D | 1 |
| Roncallo, C | 1 |
| de Pasquale, T | 1 |
| Buonomo, A | 1 |
| Pollastrini, E | 1 |
| Patriarca, G | 1 |
2 other studies available for nimodipine and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Delayed-type allergy to oral nimodipine.
Topics: Administration, Oral; Aged; Allergens; Drug Eruptions; Drug Hypersensitivity; Follow-Up Studies; Hum | 2002 |
Cutaneous drug reaction case reports: from the world literature.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Benzamides; Clozapine; Cyclosporine; Diclofena | 2003 |